Halozyme's lead drug flops in PhIII, forcing CEO to ax 160 and reset focus on tech platform
Halozyme’s lead drug has crashed and burned in Phase III, forcing CEO Helen Torley to scrap the entire program, trigger a company restructuring to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
